New Tool: ProSource
Check out our packaging and processing solutions finder, ProSource.

High Demand Strains Weight-Loss Drug Supply

Novo Nordisk and Eli Lilly are witnessing soaring demand for their diabetes and weight-loss drugs.

David J Phillip
David J. Phillip

According to a recent Reuters article, Novo Nordisk and Eli Lilly are dealing with soaring demand for their weight-loss drugs, Wegovy, Ozempic, and Mounjaro. The drugs have exceeded sales expectations, creating challenges in meeting the increasing demand. Supply constraints have arisen due to the global boom in obesity treatments. Lilly's Mounjaro, initially approved for type 2 diabetes but increasingly used off-label for weight loss, is expected to see U.S. approval for obesity treatment soon, further straining supply. The supply issues are indicative of the growing popularity of these drugs as people seek non-invasive weight-loss solutions outside of diet and exercise.

The success of these drugs has ignited a buying frenzy in Novo and Lilly shares, with both companies experiencing substantial stock price increases in 2023. These drugs have also impacted the healthcare industry and could potentially influence the demand for food and related products, given their effectiveness in managing conditions exacerbated by excess weight. 

Discover Our Content Hub
Access Healthcare Packaging's free educational content library!
Read More
Discover Our Content Hub
How to Honor a Leader
Induction into the Packaging & Processing Hall of Fame is the highest honor in our industry. Submit your leader to be considered for the Class of 2024 now through June 10th. New members will be inducted at PACK EXPO International in Chicago.
Read More
How to Honor a Leader